About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

T-cell Lymphoma >  abstracts - ASH 2012

Last update: 11/23/2012

Grouped by:

Outcomes:
Reports | SCT | Novel Agents and Combination

Biomarkers - Prognostic / Predictive / Risk Factors
PET imaging and Diagnostic  | Origin of - risk factors

Comments or Questions?

OUTCOME REPORTS

  1. Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial
  2. Treatment Outcome in T-Cell Lymphoblastic Lymphoma in Adults - a Population-Based Study From the Swedish Lymphoma Registry
  3. A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671
  4. Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial
  5. Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment
  6. First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
  7. Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
  8. Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience
  9. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma
  10. Trends in Incidence and Outcome in T-Cell Lymphoma Since 1992: A SEER Database Analysis
  11. Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin’s Lymphoma Treated with Splenectomy
  12. Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes
  Return

AUTO and ALLO SCT

  1. Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg
  2. Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance
  3. Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT)
  4. Improved Outcome After Allogeneic Stem-Cell Transplantation (SCT) As Compared to Non-Allogeneic SCT Therapies in Patients with High-Risk Peripheral T-Cell Lymphomas in First Response
  5. Role of Front-Line High Dose Therapy with Stem Cell Transplant in Peripheral T-Cell Lymphomas. A Single Center Experience.
  6. Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma
  7. Role of Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia in an HTLV-1 Non-Endemic Area of Japan
  8. Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates
  9. Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma
  10. Long-Term Remission After Hematopoietic Stem Cell Transplantation for Refractory Cutaneous T Cell Lymphoma
  11. Full Dose Treosulfan Based Reduced Toxicity Conditioning Regimen in Allogeneic Stem Cell Transplantation: Results in 123 Patients
  12. Donor Lymphocyte Infusions (DLI) Following Haplo Bone Marrow Transplantation (hBMT) with High-Dose of Cyclophosphamide Post-Transplant As Gvhd Prophylaxis
  13. Bendamustine (Treanda®), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells
  14. Impact of Graft-Versus-Host Disease On Relapse After Allogeneic Hematopoietic Stem Cell Transplantation, an EBMT Megafile Study
  15. Favorable Outcome in Patients with Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine and Treosulfan As the Preparative Regimen
  Return

NOVEL AGENTS or COMBINATIONS

Items in this section will be technical ... could be helpful when choosing clinical trials

  1. Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors
  2. Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies
  3. Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas
  4. Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T‑Cell and NΚ‑Cell Lymphomas
  5. Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
  6. A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study
  7. Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06-0002 Study Update
  8. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma
  9. Abexinostat (S78454 / PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients
  10. Multicenter Phase I Dose-Escalation Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL)
  11. Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma
  12. Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response
  13. Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma
  14. Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma
  15. The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models
  16. The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry
  17. Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor
  18. Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models
  19. Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
  20. CD30 Is a Potential Therapeutic Target in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma Presenting Outside of Japan
  21. Biomimetic Synthetic High Density Lipoprotein Nanostructures Target the SR-B1 Receptor and Differentially Manipulate Cellular Cholesterol Flux in Lymphoma Cells: A Novel Treatment Paradigm
  22. L-Asparaginase Monotherapy in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of A Phase II Study
  23. AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models
  24. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma
  25. Comprehensive Immunohistochemical Approach of AKT/mTOR Pathway and p-STAT3 in Mycosis Fungoides
  26. Genetic or Pharmacological Reductions in DNA Methylation Selectively Inhibit Peripheral T-Cell Lymphomagenesis     
  27. A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results
  28. 703. Adoptive Immunotherapy: Poster II
  29. Harnessing Invariant Natural Killer T Cells for Cancer Therapy

 Return

PET IMAGING and DIAGNOSTIC

  1. The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP
  2. Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group
  3. Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN
  4. Digital Pathology for the Assessment of Tissue Microarrays in Peripheral T-Cell Lymphomas
  5. Clonosight: A Standardized Clinical Assay for Measurement of Minimal Residual Disease in Leukemias and Lymphomas

 Return


BIOMARKERS: PREDICTIVE/PROGNOSTIC / RISK FACTORS

Much of this section is technical and preclinical. 
Note: prognostic factors are not predictive of individual outcomes.

  1. Clinicopathologic Features, Prognosis, and Therapeutic Responses in Patients with Granulomatous Mycosis Fungoides: A Single Center Experience From Memorial Sloan Kettering Cancer Center
  2. Monocytosis As Prognostic Factor in Aggressive, Non-Primary Cutaneous Peripheral T-Cell Lymphoma: A Study of 251 Cases
  3. Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas
  4. Molecular Analysis of Primary Cutaneous Aggressive T-Cell Lymphomas: the Epidermotropic CD8+, the Pleomorphic CD8+ and the Gamma Delta Subsets
  5. Reduced Expression of HDAC3 Contributes to the Resistance Against HDAC Inhibitor, Vorinostat (SAHA) in Mature Lymphoid Malignancies
  6. Role of STAT3 and Th17 Cells in Cutaneous T Cell Lymphoma
  7. Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project
  8. Kruppel-Like Factor, Klf9, Promotes Proliferation of Notch-Independent Precursor T-Cell Lymphoblastic Lymphomas
  9. Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate
  10. Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry
  11. Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort
  12. Identification of Multiple Subclones in Peripheral T-Cell Lymphoma, Not Otherwise Specified with Genomic Aberrations
  13. Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas
  14. Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers
  15. International Prognostic Index, Serum IgA Level, and Monocytes Count Are Independently Associated with Overall Survival in Patients with HTLV-I-Negative Nodal Peripheral T-Cell Lymphoma
  16. Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)
  17. Small Nucleolar RNA Expression Profiling Identifies Potential Prognostic Markers in Peripheral T-Cell Lymphoma
  18. Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort
  19. Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma
  20. A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma: Association Between Advanced Age and Mutations in TET2 and DNMT3A
  21. Serum Ferritin Level As a Prognostic Factor for Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type
  22. TET2 Mutations Revealed by Whole Genome Sequencing in Adult T-Cell Leukemia
  23. Flow Cytometric Assessment of the T-Cell Receptor Vβ Repertoire Identifies Clonal T-Cell Populations with High Specificity and Sensitivity
  24. Gene Expression Profiling of Murine T-Cell Lymphoblastic Lymphoma Identifies Deregulation of S-Phase Initiating Genes
  25. Bispecific SCORPION™ Molecules Effectively Redirect T-Cell Cytotoxicity Toward CD19-Expressing Tumor Cells
  26. CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis

 Return

ORIGIN OF - RISK FACTORS

  1. Reduced Tet2 Function Contributes to Development of Peripheral T-Cell Lymphoma with Follicular Helper T-Cell-Like Features in Mice
  2. EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer / T-Cell Lymphoma
  3. Residence Proximity to Benzene Release Sites Is Associated with Increased Incidence of Non-Hodgkin Lymphoma
  4. Illegitimate V(D)J Recombination Involving Notch1 and Bcl11b in Precursor T-Cell Lymphoblastic Leukemia/Lymphoma
  5. Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis
  6. Occurence of Malignancies in Patients with Primary Immunodeficiencies: An Analysis of the French Primary Immunodeficency Registry
  7. Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe
  8. Virally Driven Lymphomas

 Return

 

 

See also Other Ways to Help


 

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.